Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cefaclor
Drug ID BADD_D00378
Description Semisynthetic, broad-spectrum antibiotic derivative of cephalexin.
Indications and Usage For the treatment of certain infections caused by bacteria such as pneumonia and ear, lung, skin, throat, and urinary tract infections.
Marketing Status approved
ATC Code J01DC04
DrugBank ID DB00833
KEGG ID D00256; D02352
MeSH ID D002433
PubChem ID 51039
TTD Drug ID D0PW7C
NDC Product Code 0093-1087; 23594-250; 23594-375; 23594-125; 61442-171; 61442-172; 81948-6250
UNII 69K7K19H4L
Synonyms Cefaclor | Cefaclor Anhydrous | Keclor | 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, (6R-(6alpha,7beta(R*)))- | S-6472 | S 6472 | S6472 | Ceclor | Cefaclor Monohydrate | Lilly 99638
Chemical Information
Molecular Formula C15H14ClN3O4S
CAS Registry Number 53994-73-3
SMILES C1C(=C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)O)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Somnolence17.02.04.006; 19.02.05.003--
Stevens-Johnson syndrome10.01.01.045; 11.07.01.005; 12.03.01.014; 23.03.01.007--
Stomatitis07.05.06.005--
Superinfection11.01.08.009---
Swelling face08.01.03.100; 10.01.05.018; 23.04.01.0180.000049%-
Syncope02.11.04.015; 17.02.04.008; 24.06.02.012--
Tension19.06.02.005---
Thrombocytopenia01.08.01.002---
Thrombocytosis01.08.02.001---
Tongue oedema07.14.02.007; 10.01.05.008; 23.04.01.009---
Tooth discolouration07.09.02.001--
Toxic epidermal necrolysis10.01.01.006; 11.07.01.006; 12.03.01.015; 23.03.01.008--
Tremor17.01.06.002--
Urethral disorder20.07.01.002---
Urinary tract disorder20.08.01.001---
Urine glucose false positive13.02.02.006---
Urticaria10.01.06.001; 23.04.02.0010.000073%
Vaginal discharge21.08.02.002--
Vaginal infection11.01.10.002; 21.14.02.002--
Vasodilatation23.06.05.006; 24.03.02.003---
Vertigo04.04.01.003; 17.02.12.002--
Vomiting07.01.07.0030.000097%
Vulvovaginal candidiasis11.03.03.005; 21.14.02.003---
Wheezing22.03.01.009--
Tubulointerstitial nephritis20.05.02.002---
Lymphatic disorder01.09.01.003---
Musculoskeletal discomfort15.03.04.001---
Type IV hypersensitivity reaction10.01.03.0220.000049%-
Affect lability19.04.01.001---
Foetal death08.04.01.011; 18.01.02.0030.000146%
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene